Ontology highlight
ABSTRACT:
SUBMITTER: Ciscar M
PROVIDER: S-EPMC10086586 | biostudies-literature | 2023 Apr
REPOSITORIES: biostudies-literature
Ciscar Marina M Trinidad Eva M EM Perez-Chacon Gema G Alsaleem Mansour M Jimenez Maria M Jimenez-Santos Maria J MJ Perez-Montoyo Hector H Sanz-Moreno Adrian A Vethencourt Andrea A Toss Michael M Petit Anna A Soler-Monso Maria T MT Lopez Victor V Gomez-Miragaya Jorge J Gomez-Aleza Clara C Dobrolecki Lacey E LE Lewis Michael T MT Bruna Alejandra A Mouron Silvana S Quintela-Fandino Miguel M Al-Shahrour Fatima F Martinez-Aranda Antonio A Sierra Angels A Green Andrew R AR Rakha Emad E Gonzalez-Suarez Eva E
EMBO molecular medicine 20230307 4
Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor-negative, ER<sup>-</sup> ) from four independent cohorts. RANK protein expression was more frequent in ER<sup>-</sup> tumors, where it associated with poor outcome and poor response to ...[more]